the company has focused on only 3 product endeavors, 2 Gleasman legacies (pump & differential) and the CURA alertness system. The diff could not be perfected so they suspended work on it to concentrate on the pump and CURA. So far no big obstacles are cited in the path of the pump or CURA, and Kaplan has said they're almost ready. And many shareholders are trusting him.
I've often said here the Gleasmans were involved in too many things at once during their primary tenure (of course, Keith is still senior management). Then again, early on, they thought they had the funding to pursue everything -- based on the Swartz line of credit. They developed a budget based on it. They didn't know at the time that embedded in the financing were the means to instead starve them to death. A few years later a so-called professional management team was hired by the Gleasmans. It didn't work out well either; major litigation, allegations of sabotage, and, as I heard it, a NYS judge comenting that the situation looked like an attempt to steal the company from the Gleasmans and all the other shareholders.
So, for years, the Gleasmans had to tend to business, all the while terribly understaffed, constantly scraping around for money to pay the bills, battling in court, holding nervous shareholders' hands every day, and being attacked from many sides. And, yes, still pursuing too many things at once. But it's a wonder the company survived and they got anything done. Yet they continued to develop. The stress that the company and its personnel and its shareholders suffered year in and year out, and still do. So even though I wasn't substantially invested during the earlier times I described, I knew to keep my eye on them nonetheless.
Mama there's wolves in the house, Mama I tried to put them out, And Mama I know you're too wise, To wait till those wolves make nice. -- "Wolves", Matt Houck